Skip to main content

Antibody-mediated Rejection in Kidney Transplant

Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection
NCT05452317 | PHASE 3 | OBSERVATIONAL

This study investigates the burden of disease among kidney transplant recipients that have developed Chronic Active Antibody Mediated Rejection (caAMR) compared with kidney transplant recipients that have not developed caAMR

Trial Information
3 Sites
52 Participants
Recruiting
18 Years to 64 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Keck Medical Center of USC
Los Angeles,California,United States,90033
University of Maryland School of Medicine, Div. of Nephrology
Baltimore,Maryland,United States,21201
The Washington University
Saint Louis,Missouri,United States,63130

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov